{"analyses":[{"ciLowerLimit":"-1.8","ciPctValue":"97.5","ciUpperLimit":"5.7","groupDescription":"A non-inferiority assessment determined whether degarelix was non-inferior to leuprolide with respect to the cumulative probability of testosterone \\<=0.5 ng/mL from Day 28 to Day 364.","groupIds":["OG000","OG002"],"nonInferiorityComment":"The non-inferiority limit was -10 percentage points.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Difference in cumulative probability","paramValue":"1.9","testedNonInferiority":true},{"ciLowerLimit":"-3.2","ciPctValue":"97.5","ciUpperLimit":"5.0","groupDescription":"A non-inferiority assessment determined whether degarelix was non-inferior to leuprolide with respect to the cumulative probability of testosterone \\<=0.5 ng/mL from Day 28 to Day 364.","groupIds":["OG001","OG002"],"nonInferiorityComment":"The non-inferiority limit was -10 percentage points.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Difference in cumulative probability","paramValue":"0.9","testedNonInferiority":true}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"94.8","upperLimit":"99.4","value":"98.3"},{"groupId":"OG001","lowerLimit":"93.5","upperLimit":"98.8","value":"97.2"},{"groupId":"OG002","lowerLimit":"92.5","upperLimit":"98.2","value":"96.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"207"},{"groupId":"OG002","value":"201"}],"units":"Participants"}],"description":"Kaplan-Maier estimates of the cumulative probabilities of testosterone \\<=0.5 ng/mL from Day 28 to Day 364. The degarelix response rate estimation determined whether the lower bound of the 95% confidence interval for the cumulative probability of testosterone \\<=0.5 ng/mL from Day 28 to Day 364 was no lower than 90%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.","id":"OG000","title":"Degarelix 240/160 mg"},{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.","id":"OG001","title":"Degarelix 240/80 mg"},{"description":"Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.","id":"OG002","title":"Leuprolide 7.5 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-treat (ITT) population.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Percentage of Patients With Testosterone <=0.5ng/mL From Day 28 Through Day 364","type":"PRIMARY","unitOfMeasure":"percentage of patients"}